Search results for "poor prognosis"

showing 10 items of 46 documents

Live birth after embryo transfer in an unresponsive thin endometrium.

2014

A healthy term livebirth in a 35-year-old woman with ovarian failure, hypoplastic uterus and atrophic endometrium after cancer treatment with chemotherapy and radiotherapy was achieved by ovum donation. The detection of a receptive endometrium using a new diagnostic tool of endometrial receptivity encouraged the medical team to carry on with this poor prognosis case. To the best of our knowledge, here we report the thinnest endometrium to date in which a healthy, full term live birth has been described in assisted conception.

Adultmedicine.medical_specialtyPoor prognosisTerm BirthEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndometriumAtrophic endometriumEndometriumEndocrinologyPregnancymedicineHumansEmbryo ImplantationFull TermGynecologyOocyte Donationurogenital systemObstetricsbusiness.industryGene Expression ProfilingInfant NewbornObstetrics and GynecologyEmbryo Transferfemale genital diseases and pregnancy complicationsEmbryo transferRadiation therapymedicine.anatomical_structureFemaleEndometrial receptivityLive birthbusinessGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-ar…

2020

e15209 Background: Balixafortide (B) is a potent, selective antagonist of the chemokine receptor CXCR4. High CXCR4 levels correlate with aggressive metastatic phenotypes and poor prognosis in metastatic breast cancer (MBC). Efficacy and safety data were published recently from the Phase 1 trial investigating B + eribulin (E) in patients with HER2 negative MBC1. We report the final efficacy analyses from this trial, including assessment of dose-response. Methods: In this single-arm, dose escalation trial, patients (pts) received E + increasing doses of B using a 3+3 design in 3 parts: Part I (cohorts received low E doses); Part II (dose-escalation cohort for B [1−5.5mg/kg] + 1.4mg/m2 E); Ex…

Cancer ResearchPoor prognosisCXCR4 antagonistbusiness.industryHER2 negativeSelective antagonistmedicine.diseaseCXCR4Metastatic breast cancer03 medical and health scienceschemistry.chemical_compoundChemokine receptor0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisCancer researchMedicinebusiness030215 immunologyEribulinJournal of Clinical Oncology
researchProduct

Role of PD-L1 expression in triple-negative breast cancer stem cells.

2018

12081Background: Triple negative breast cancer (TNBC) is characterized by poor prognosis, lack of specific-targeted agents and is in need of new therapeutics. Immune checkpoint blockers have shown ...

Cancer ResearchPoor prognosisOncologybusiness.industryCancer researchMedicinePd l1 expressionStem cellbusinessTriple-negative breast cancerImmune checkpointJournal of Clinical Oncology
researchProduct

LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced…

2014

4081 Background: Patients (pts) with LAEC have a poor prognosis; new therapies are required. A study showed the addition of Cet to RCT to be safe and effective for resectable EC [Ruhstaller et al, ...

CisplatinOncologyCancer ResearchPoor prognosismedicine.medical_specialtyCetuximabbusiness.industryLocally advancedPhases of clinical researchEsophageal cancermedicine.diseaselaw.inventionOncologyRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Karyotype analysis and marker chromosomes of renal cell carcinoma.

1988

Karyotyping was performed in 46 human renal cell carcinomas of various histological grades. Controls included chromosome analysis of normal renal parenchymal cells from the same patients. Various numerical chromosome aberrations were found as well as marker chromosomes. They are specific of the individual tumor but no single marker was identified occurring in all tumors tested. Only trisomy 3 was found in different tumors (31%), suggesting a more general character of this aberration. Histological dedifferentiation and large tumor size correlate with focusing of the karyotype towards distinct chromosomal modes indicative of distinct tumor cell subclones within these tumors. Their rapid growt…

Genetic MarkersPathologymedicine.medical_specialtyPoor prognosisbusiness.industryUrologyCellChromosomeKaryotypeTrisomymedicine.diseaseKidneyKidney Neoplasmsmedicine.anatomical_structureChromosome 3Renal cell carcinomaKaryotypingParenchymamedicineHumansRing ChromosomesHistological gradesChromosomes Human Pair 3businessCarcinoma Renal CellEuropean urology
researchProduct

Experimental Hypertensive Intracerebral Mass Hemorrhage in Cats

1986

About two–thirds of all patients with spontaneous intracerebral hemorrhage suffer from systemic hypertension. Additionally systemic hypertension is the main factor indicating a poor prognosis of intracerebral hemorrhage. This has been shown in our statistical evaluation of 117 cases of conservatively treated spontaneous intracerebral hemorrhage. More than 48% of the hypertensive patients died, but only 30% of the normotensive patients (Fig. 1). In an experimental study we investigated the influence of systemic hypertension and normotension on epidural pressure and on the formation of brain edema during the first 12 h after artificial intracerebral hemorrhage.

Intracerebral hemorrhagePoor prognosisVasogenic edemaCATSbusiness.industryBrain edemaAnesthesiamedicineSpontaneous intracerebral hemorrhagemedicine.diseasebusinessHypertensive group
researchProduct

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

2019

The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and JAK2 V617F presence. The revised IPSET-thrombosis uses three adverse variables to delineate four risk categories: age greater than 60, thrombosis history, and JAK2 V617F presence. We compared different risk models in the estimation of thrombotic risk in 191 patients with ET and the role of specific driver mutations affecting overall survival, according to thrombotic risk. …

MaleCancer ResearchEssential Thrombocythemia Myeloproliferative Thrombosis Thrombotic risk SurvivalKaplan-Meier EstimateSeverity of Illness IndexSettore MED/15 - Malattie Del SanguePrognostic score0302 clinical medicineRisk groupsRecurrenceRisk FactorsMutational statusThrombophiliaAged 80 and overIncidenceAge FactorsHematologyGeneral MedicineMiddle AgedPrognosisThrombosisOncology030220 oncology & carcinogenesisFemaleJAK2 V617FReceptors ThrombopoietinThrombocythemia EssentialAdultPoor prognosismedicine.medical_specialtyAdolescentMutation MissenseModels BiologicalRisk Assessment03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedRetrospective StudiesThrombotic riskbusiness.industryEssential thrombocythemiaThrombosisJanus Kinase 2medicine.diseasebusinessCalreticulin030215 immunologyFollow-Up StudiesHematological oncologyREFERENCES
researchProduct

Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

2017

Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI.During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (30 U/mL) and EuroSCORE (median) (47% vs 20%, P.001 and 38% vs 16%, P.001, respectively). In the multivariable analysis, CA125 (30 U/mL) remained an independent predictor of mortality …

MaleLogistic euroscoremedicine.medical_specialtyPoor prognosisTranscatheter aortic610 Medicine & health030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness Index2705 Cardiology and Cardiovascular MedicineTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineProspective Studies030212 general & internal medicineAgedTumor markerbusiness.industryHazard ratioMembrane ProteinsEuroSCOREAortic Valve StenosisGeneral MedicinePrognosisConfidence intervalCA-125 AntigenRisk stratification10209 Clinic for CardiologyCardiologyFemalebusinessRevista Española de Cardiología (English Edition)
researchProduct

Italian clinical research in non-small-cell lung cancer

2005

ABSTRACT Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15–20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC p…

MaleOncologymedicine.medical_specialtyPoor prognosisLung NeoplasmsNSCLCCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedClinical Trials as TopicLungbusiness.industryStandard treatmentCancerHematologymedicine.diseaseItalian clinical researchrespiratory tract diseasesSurvival RateClinical trialTreatment OutcomeClinical researchmedicine.anatomical_structureItalyOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantNon small cellCisplatinLung cancerbusiness
researchProduct

A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

2014

MaleOncologymedicine.medical_specialtyPoor prognosisSkin NeoplasmsHistologyMultivariate analysisMEDLINEPathology and Forensic MedicineText miningInternal medicinemedicineHumansIn patientMelanomaCD20biologybusiness.industryMelanomaDisease progressionGeneral MedicineAntigens CD20Prognosismedicine.diseaseMultivariate AnalysisDisease Progressionbiology.proteinFemalebusinessHistopathology
researchProduct